Log In
BCIQ
Print this Print this
 

TIMP/Gliadin

  Manage Alerts
Collapse Summary General Information
Company Cour Pharmaceutical Development Co. Inc.
DescriptionGliadin delivered using the Tolerizing Immune Modifying nanoParticle (TIMP) platform
Molecular Target
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard IndicationCeliac disease
Indication DetailsTreat celiac disease
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/07/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today